Nouscom’s NOUS-209 viral vector neoantigen vaccine earns FDA Fast Track for Lynch Syndrome cancer prevention

Nouscom, a clinical-stage biotech headquartered in Basel, Switzerland, announced receipt of US FDA Fast Track Designation for NOUS-209, a viral vector-based, off-the-shelf neoantigen cancer vaccine, for the prevention of Lynch Syndrome (LS)-associated cancers in carriers with genetically confirmed mismatch repair (MMR) mutations. The designation, granted June 1, 2026, makes NOUS-209 eligible for rolling review and Priority Review of a future Biologics License Application (BLA), and opens the door to Accelerated Approval.

Fast Track Designation is reserved for therapies targeting serious conditions where clinical need is inadequately addressed. For Nouscom, the designation also formalizes more frequent FDA interactions as the company prepares its registration-enabling trial.

NOUS-209 encodes 209 shared frameshift peptide (FSP) neoantigens — mutation-derived antigens that arise specifically in dMMR/MSI tumors and are absent from healthy tissue — delivered via two proprietary viral vectors in a heterologous prime-boost regimen. Because FSP neoantigens are shared across patients with MMR-deficient tumors, the construct can be manufactured as an off-the-shelf product, distinguishing it from personalized neoantigen approaches such as Nouscom’s own NOUS-PEV program.

The clinical case for the designation rests on Phase 1b/2 data in 45 LS carriers, published in Nature Medicine in January 2026 (D’Alise et al., 2026). All evaluable participants developed T cell responses against FSP neoantigen pools, measured by ex vivo IFNγ ELISpot assay, with annual retreatment shown to boost responses. Vaccine-induced T cells demonstrated direct tumor cell killing activity in functional assays. Crucially, no new advanced adenomas were detected at one-year post-treatment colonoscopy — a finding the company characterizes as the first clinical evidence of cancer interception in LS carriers. No formal comparative p-value was reported, consistent with the single-arm design. The trial is registered as NCT05078866.

Earlier mechanistic and safety data came from a Phase Ib study in advanced dMMR/MSI-H metastatic colorectal cancer (mCRC), published in Science Translational Medicine in 2022 (D’Alise et al.), which established proof-of-concept for FSP neoantigen-directed T cell priming. NOUS-209 is also under evaluation in two Phase II studies in combination with pembrolizumab: one in anti-PD-1-refractory advanced dMMR/MSI-H mCRC, and one in first-line dMMR/MSI-H mCRC. Specific NCT identifiers for those Phase II studies were not provided in the announcement.

Research context

LS is caused by germline mutations in MMR genes — most commonly MLH1, MSH2, MSH6, and PMS2 — leading to microsatellite instability and a cumulative mutational burden that drives tumor formation across multiple organ systems. Lifetime colorectal cancer risk reaches up to 50% in LS carriers, compared with approximately 2% in the general population; endometrial cancer risk reaches a similar ceiling, and urothelial cancer risk approaches 25%. The condition also elevates risk for gastric, ovarian, prostate, and pancreatic malignancies.

Current management is confined to intensive endoscopic surveillance and prophylactic surgery. No pharmacological cancer prevention therapy is approved for LS carriers anywhere in the world. Aspirin has been studied as a chemopreventive agent in LS under the CAPP2 and CAPP3 trials, with CAPP2 reporting a reduction in LS-associated cancer incidence at ten-year follow-up.

In the MSI-H/dMMR metastatic setting — where NOUS-209 is also being studied — pembrolizumab holds FDA approval as first-line monotherapy, and dostarlimab has approval in dMMR endometrial cancer. Both are checkpoint inhibitors acting on PD-1/PD-L1 axes. NOUS-209 operates through an orthogonal mechanism: active immunization to generate de novo FSP-specific T cells, rather than releasing pre-existing but suppressed immune activity. In the prevention context, where patients are not yet immunologically tolerized to established tumors, the active vaccination approach may carry mechanistic advantages that checkpoint blockade alone cannot replicate. Whether that translates into clinical superiority remains to be demonstrated in the registration-enabling trial.

Nouscom has not disclosed the design or timeline of that planned Phase II/III study, beyond stating that FDA and EMA alignment on the registrational path has been achieved. The Fast Track Designation will facilitate rolling BLA submission once data mature, potentially compressing the gap between trial completion and regulatory decision.